Jade Biosciences, Inc.

For the period ended Mar 31, 2025. Filed Apr 25, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed Apr 25, 2025

JBIO$15.60+3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)


· · March 31, · · December 31, ·
· 2025 · 2024
Assets · · ·
Current assets: · · ·
Cash and cash equivalents	$44,220	$33,751
Short-term investments	31,990	44,872
Prepaid expenses and other current assets	1,163	1,494
Total current assets	77,373	80,117
Property and equipment, net	2	6
Operating lease right-of-use assets	158	209
Total assets	$77,533	$80,332

Liabilities and Stockholders’ Equity

Current liabilities:
Accounts payable	$69	$224
Accrued and other current liabilities	2,036	3,187
Operating lease liabilities	312	417
Total current liabilities	2,417	3,828
Other liabilities	70	70
Total liabilities	2,487	3,898

Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2025 and December 31, 2024, respectively; no shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	—	—
Common stock, $0.0001 par value; 150,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; 28,985,019 and 27,762,703 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	3	3
Additional paid-in capital	310,563	309,378
Accumulated other comprehensive gain	50	105
Accumulated deficit	(235,570)	(233,052)
Total stockholders’ equity	75,046	76,434
Total liabilities and stockholders’ equity	$77,533	$80,332

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.